ERBB2 and neoplasm: Targeting two non-overlapping epitopes of HER2 using a combination of antibodies or a bispecific molecule induced accelerated internalization and degradation of HER2 receptors [34,36,37,41] as well as enhanced anti-tumor-inhibitory activity [37,41,48,49].